Larazotide Acetate (5mg)

What is Larazotide Acetate?

An octapeptide that antagonizes zonulin signaling to maintain intestinal epithelial tight-junction integrity.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Larazotide acetate (AT-1001) is an eight-amino-acid peptide that antagonizes zonulin, an endogenous regulator of intestinal tight junctions. By blocking zonulin-induced disassembly of zonula occludens proteins, larazotide preserves epithelial barrier integrity and reduces paracellular antigen translocation.

What are the research questions?

• Celiac disease research: Phase 2b trial (Leffler DA et al., Gastroenterology 2015) demonstrated reduced gluten-triggered symptoms in patients on gluten-free diet with persistent symptoms.
• Intestinal permeability research: A reference tool compound for tight-junction biology and zonulin pharmacology.
• Autoimmunity and IBD models: Investigated for any barrier-driven autoimmune pathology including type 1 diabetes models.

What does the published work describe?

Leffler DA et al. (Gastroenterology 2015) — significant symptom reduction vs placebo. Phase 3 CeDLara trial (2022) did not meet its primary endpoint, ending pivotal development but preserving the research utility of the compound.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Leffler DA et al. Gastroenterology 2015
2. Slifer ZM & Blikslager AT. Int J Mol Sci 2020

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Larazotide Acetate handled in the lab?

Plan a Larazotide Acetate stock solution from the sequence, the listed molecular weight (1149.30 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave